Table 4.
Studies of prophylactic cranial irradiation for patients with locally advanced non-small cell lung cancer in recursive partitioning analysis group 1.
| Reference | N patients | Histology | Primary Tx | Dose of PCI | BM PCI- (%) | BM PCI+ (%) | P-value |
| Albain et al.1 | 126 | All NSCLC | Trimodality | 36 Gy (2 Gy/fr) | 16 | 8 | 0.36 |
| Strauss et al.4 | 54 | Non-squamous | Trimodality | 30 Gy (2 Gy/fr) | 12 | 0 | 0.32 |
| Skarin et al.12 | 41 | All NSCLC | Trimodality | NS | 27 | 14 | |
| Rusch et al.11 | 75 | NS | Ctx+TRT | 36 Gy (2 Gy/fr) 30 Gy (3 Gy/fr) |
- | 0 | - |
| Stuschke et al.10 | 75 | All NSCLC | Trimodality | 30 Gy (2 Gy/fr) | 54 | 13 | 0.0004 |
| Cox et al.5 | 281 | All NSCLC | TRT | 20 Gy (2 Gy/fr) | 13 | 6 | 0.038 |
| Unsawasdi.7 | 97 | All NSCLC | Trimodality Ctx+TRT | 30 Gy (3 Gy/fr) | 27 | 4 | 0.002 |
| Russell et al.6 | 187 | Non-squamous | TRT | 30 Gy (3 Gy/fr) | 19 | 9 | 0.06 |
| Mira et al.32 | 111 | All NSCLC | Ctx + TRT | 30 Gy (2 Gy/fr) 37.5 Gy (2.5Gy/fr) |
11 | 0 | 0.0001 |
| Pöttgen et al.14 | 112 | All NSCLC (Stage IIIA) | Trimodality | 30 Gy (2 Gy/fr) | 27.2 | 9.1 | 0.02 0.04 |
| Yavuz et al.* | 62 | Squamous and adeno ca (Stage IIIB) | Ctx + TRT | 30 Gy (2 Gy/fr) | - | 9.7 | - |
(*) Current study.
Abbreviations: Tx = treatment; NSCLC = non-small cell lung cancer, Ctx = chemotherapy, TRT = thoracic radiotherapy; PCI = prophylactic cranial irradiation, BM = brain metastasis.